Global Minimal Residual Disease (MRD) Testing Market 2021-2031

Bonafide Trust 11-06-2022 170 Pages
Region : Global Category : Lifescience Healthcare

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Global minimal residual disease (MRD) testing market will reach $ 2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region. Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Services • Test Kits & Consumables Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Non-Hodgkin's Lymphoma (NHL) o DLBCL o Marginal Zone Lymphoma o Follicular Lymphoma o Peripheral T-cell Lymphoma o Mantle Cell Lymphoma o Other NHLs • Multiple Myeloma (MM) • Acute Lymphoblastic Leukemia (ALL) • Chronic Lymphoblastic Leukemia (CLL) • Acute Myeloid Leukemia (AML) • Chronic Myeloid Leukemia (CML) • Hodgkin's Lymphoma (HL) • Solid Tumor • Other Applications By Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Flow Cytometry • Polymerase Chain Reaction (PCR) • Next-Generation Sequencing (NGS) • Other Technologies By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals and Clinics • Research Institutions • Diagnostic Laboratories • Other End Users Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa, Other Nations) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Adaptive Biotechnologies Corporation ArcherDX, Inc. (Invitae Corporation) Arup Laboratories Asuragen Inc. Bio-Rad Laboratories, Inc. Cergentis B.V. Guardant Health ICON plc Inivata Ltd. Invivoscribe, Inc. Laboratory Corporation of America Holdings Mission Bio, Inc. Natera, Inc. NeoGenomics Laboratories, Inc. Opko Health, Inc. Quest Diagnostics Incorporated Sysmex Corporation (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9

1.1 Industry Definition and Research Scope 9

1.1.1 Industry Definition 9

1.1.2 Research Scope 10

1.2 Research Methodology 13

1.2.1 Overview of Market Research Methodology 13

1.2.2 Market Assumption 14

1.2.3 Secondary Data 14

1.2.4 Primary Data 14

1.2.5 Data Filtration and Model Design 15

1.2.6 Market Size/Share Estimation 16

1.2.7 Research Limitations 17

1.3 Executive Summary 18

2 Market Overview and Dynamics 21

2.1 Market Size and Forecast 21

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 24

2.2 Major Growth Drivers 26

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Global Market by Offering 43

3.1 Market Overview by Offering 43

3.2 Services 45

3.3 Test Kits & Consumables 46

4 Segmentation of Global Market by Application 47

4.1 Market Overview by Application 47

4.2 Non-Hodgkin’s Lymphoma (NHL) 49

4.2.1 DLBCL 51

4.2.2 Marginal Zone Lymphoma 52

4.2.3 Follicular Lymphoma 53

4.2.4 Peripheral T-cell Lymphoma 54

4.2.5 Mantle Cell Lymphoma 55

4.2.6 Other NHLs 56

4.3 Multiple Myeloma (MM) 57

4.4 Acute Lymphoblastic Leukemia (ALL) 58

4.5 Chronic Lymphoblastic Leukemia (CLL) 59

4.6 Acute Myeloid Leukemia (AML) 60

4.7 Chronic Myeloid Leukemia (CML) 61

4.8 Hodgkin’s Lymphoma (HL) 62

4.9 Solid Tumor 63

4.10 Other Applications 64

5 Segmentation of Global Market by Technology 65

5.1 Market Overview by Technology 65

5.2 Flow Cytometry 67

5.3 Polymerase Chain Reaction (PCR) 68

5.4 Next-Generation Sequencing (NGS) 69

5.5 Other Technologies 70

6 Segmentation of Global Market by End User 71

6.1 Market Overview by End User 71

6.2 Hospitals and Clinics 73

6.3 Research Institutions 74

6.4 Diagnostic Laboratories 75

6.5 Other End Users 76

7 Segmentation of Global Market by Region 77

7.1 Geographic Market Overview 2021-2031 77

7.2 North America Market 2021-2031 by Country 81

7.2.1 Overview of North America Market 81

7.2.2 U.S. 85

7.2.3 Canada 88

7.2.4 Mexico 90

7.3 European Market 2021-2031 by Country 92

7.3.1 Overview of European Market 92

7.3.2 Germany 96

7.3.3 U.K. 98

7.3.4 France 100

7.3.5 Spain 102

7.3.6 Italy 104

7.3.7 Netherlands 106

7.3.8 Rest of European Market 108

7.4 Asia-Pacific Market 2021-2031 by Country 110

7.4.1 Overview of Asia-Pacific Market 110

7.4.2 Japan 114

7.4.3 China 117

7.4.4 Australia 119

7.4.5 India 121

7.4.6 South Korea 123

7.4.7 Rest of APAC Region 125

7.5 South America Market 2021-2031 by Country 127

7.5.1 Argentina 130

7.5.2 Brazil 132

7.5.3 Chile 134

7.5.4 Rest of South America Market 136

7.6 MEA Market 2021-2031 by Country 137

7.6.1 UAE 140

7.6.2 Saudi Arabia 142

7.6.3 South Africa 144

7.6.4 Other National Markets 146

8 Competitive Landscape 147

8.1 Overview of Key Vendors 147

8.2 New Product Launch, Partnership, Investment, and M&A 151

8.3 Company Profiles 152

Adaptive Biotechnologies Corporation 152

ArcherDX, Inc. (Invitae Corporation) 154

Arup Laboratories 155

Asuragen Inc. 156

Bio-Rad Laboratories, Inc. 157

Cergentis B.V. 158

Guardant Health 159

ICON plc 160

Inivata Ltd. 161

Invivoscribe, Inc. 162

Laboratory Corporation of America Holdings 163

Mission Bio, Inc. 164

Natera, Inc. 165

NeoGenomics Laboratories, Inc. 166

Opko Health, Inc. 167

Quest Diagnostics Incorporated 168

Sysmex Corporation 169

RELATED REPORTS 170

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 18
Figure 4. Global Minimal Residual Disease Testing Market, 2021-2031, $ mn 21
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Global Minimal Residual Disease Testing Market 26
Figure 7. World Number of Deaths from Cancers in 201 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Global Minimal Residual Disease Testing Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Global Minimal Residual Disease Testing Market 39
Figure 13. Breakdown of Global Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 44
Figure 14. Global Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 44
Figure 15. Global Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 45
Figure 16. Global Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 46
Figure 17. Breakdown of Global Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 48
Figure 18. Global Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 48
Figure 19. Global Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 49
Figure 20. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 51
Figure 21. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 52
Figure 22. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 53
Figure 23. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 54
Figure 24. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 55
Figure 25. Global Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 56
Figure 26. Global Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 57
Figure 27. Global Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 58
Figure 28. Global Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 59
Figure 29. Global Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 60
Figure 30. Global Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 61
Figure 31. Global Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 62
Figure 32. Global Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 63
Figure 33. Global Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 64
Figure 34. Breakdown of Global Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 66
Figure 35. Global Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 66
Figure 36. Global Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 67
Figure 37. Global Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 68
Figure 38. Global Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 69
Figure 39. Global Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 70
Figure 40. Breakdown of Global Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 72
Figure 41. Global Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 72
Figure 42. Global Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 73
Figure 43. Global Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 74
Figure 44. Global Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 75
Figure 45. Global Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 76
Figure 46. Global Market Snapshot by Region 77
Figure 47. Geographic Spread of Worldwide Minimal Residual Disease Testing Market, 2021-2031, % of Sales Revenue 78
Figure 48. Global Addressable Market Cap in 2022-2031 by Region, Value ($ mn) and Share (%) 79
Figure 49. North American Minimal Residual Disease Testing Market, 2021-2031, $ mn 82
Figure 50. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 83
Figure 51. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 52. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 86
Figure 53. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 88
Figure 54. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 90
Figure 55. European Minimal Residual Disease Testing Market, 2021-2031, $ mn 93
Figure 56. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 94
Figure 57. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 95
Figure 58. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn 96
Figure 59. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn 98
Figure 60. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn 100
Figure 61. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn 102
Figure 62. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn 104
Figure 63. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn 106
Figure 64. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn 108
Figure 65. Asia-Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn 111
Figure 66. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 111
Figure 67. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 113
Figure 68. Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn 115
Figure 69. Minimal Residual Disease Testing Market in China, 2021-2031, $ mn 117
Figure 70. Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn 119
Figure 71. Minimal Residual Disease Testing Market in India, 2021-2031, $ mn 121
Figure 72. Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn 123
Figure 73. Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn 125
Figure 74. South America Minimal Residual Disease Testing Market, 2021-2031, $ mn 128
Figure 75. Breakdown of South America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 128
Figure 76. Contribution to South America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 129
Figure 77. Minimal Residual Disease Testing Market in Argentina, 2021-2031, $ mn 130
Figure 78. Minimal Residual Disease Testing Market in Brazil, 2021-2031, $ mn 132
Figure 79. Minimal Residual Disease Testing Market in Chile, 2021-2031, $ mn 134
Figure 80. Minimal Residual Disease Testing Market in Rest of South America, 2021-2031, $ mn 136
Figure 81. Minimal Residual Disease Testing Market in Middle East and Africa (MEA), 2021-2031, $ mn 138
Figure 82. Breakdown of MEA Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 138
Figure 83. Contribution to MEA 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 139
Figure 84. Minimal Residual Disease Testing Market in UAE, 2021-2031, $ mn 140
Figure 85. Minimal Residual Disease Testing Market in Saudi Arabia, 2021-2031, $ mn 142
Figure 86. Minimal Residual Disease Testing Market in South Africa, 2021-2031, $ mn 144
Figure 87. Growth Stage of Global Minimal Residual Disease Testing Industry over the Forecast Period 147

List of Tables:

Table 1. Snapshot of Global Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031 19
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 31
Table 4. Main Product Trends and Market Opportunities in Global Minimal Residual Disease Testing Market 35
Table 5. Global Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn 43
Table 6. Global Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 47
Table 7. Global Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn 50
Table 8. Global Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 65
Table 9. Main Vendors and Products of Flow Cytometry Technology 67
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology 68
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology 69
Table 12. Global Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 71
Table 13. Global Minimal Residual Disease Testing Market by Region, 2021-2031, $ mn 78
Table 14. Leading National Minimal Residual Disease Testing Market, 2021 and 2031, $ mn 80
Table 15. North America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 83
Table 16. U.S. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 87
Table 17. U.S. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 87
Table 18. U.S. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 87
Table 19. Canada Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 89
Table 20. Canada Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 89
Table 21. Canada Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 89
Table 22. Mexico Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 91
Table 23. Mexico Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 91
Table 24. Mexico Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 91
Table 25. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 95
Table 26. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 97
Table 27. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 97
Table 28. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 97
Table 29. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 99
Table 30. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 99
Table 31. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 99
Table 32. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 101
Table 33. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 101
Table 34. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 101
Table 35. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 103
Table 36. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 103
Table 37. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 103
Table 38. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 105
Table 39. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 105
Table 40. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 105
Table 41. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 107
Table 42. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 107
Table 43. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 107
Table 44. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn 109
Table 45. APAC Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 112
Table 46. Japan Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 116
Table 47. Japan Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 116
Table 48. Japan Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 116
Table 49. China Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 118
Table 50. China Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 118
Table 51. China Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 118
Table 52. Australia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 120
Table 53. Australia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 120
Table 54. Australia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 120
Table 55. India Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 122
Table 56. India Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 122
Table 57. India Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 122
Table 58. South Korea Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 124
Table 59. South Korea Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 124
Table 60. South Korea Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 124
Table 61. Minimal Residual Disease Testing Market in Rest of APAC by Country/Region, 2021-2031, $ mn 126
Table 62. South America Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 129
Table 63. Argentina Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 131
Table 64. Argentina Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 131
Table 65. Argentina Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 131
Table 66. Brazil Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 133
Table 67. Brazil Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 133
Table 68. Brazil Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 133
Table 69. Chile Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 135
Table 70. Chile Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 135
Table 71. Chile Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 135
Table 72. MEA Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 139
Table 73. UAE Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 141
Table 74. UAE Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 141
Table 75. UAE Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 141
Table 76. Saudi Arabia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 143
Table 77. Saudi Arabia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 143
Table 78. Saudi Arabia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 143
Table 79. South Africa Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 145
Table 80. South Africa Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 145
Table 81. South Africa Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 145
Table 82. Breakdown of World Market by Key Vendor, 2021, % 149
Table 83. Approved and Launched MRD Testing Products of Key Vendors 149
Table 84. Adaptive Biotechnologies Corporation: Company Snapshot 152
Table 85. Adaptive Biotechnologies Corporation: Business Segmentation 153
Table 86. Adaptive Biotechnologies Corporation: Product Portfolio 153

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3480
USD

Single User License
Site License
Global User License

Client Rating

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Global Minimal Residual Disease (MRD) Testing Market 2021-2031

Global Minimal Residual Disease (MRD) Testing Market 2021-2031